Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-Amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b] pyrazol-3-yl)-quinolines

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 13, 2004, Pages 3585-3588

  Li, Hong Yu ^a   Wang, Yan ^a   Yan, Lei ^a   Campbell, Robert M ^a   Anderson, Bryan D ^a   Wagner, Jill R ^a   Yingling, Jonathan M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINO 4 (2 PYRIDIN 2 YL 5,6 DIHYDRO 4H PYRROLO[1,2 B]PYRAZOL 3 YL)QUINOLINE; ENZYME INHIBITOR; QUINOLINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA TYPE I RECEPTOR KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; NONHUMAN;

ACTIVIN RECEPTORS, TYPE I; CELLS, CULTURED; DIMERIZATION; HUMANS; INHIBITORY CONCENTRATION 50; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; PYRAZOLES; PYRROLES; QUINOLINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 2942559053     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.04.065     Document Type: Article

References (12)

1. For other TβR-1 inhibitors, see: Sawyer, J. S.; Beight, D. W.; Britt, K. S.; Anderson, B. D.; Campbell, R. M.; Goodson, T., Jr.; Herron, D. K.; Li, H.-Y.; McMillen, W. T.; Mort, N.; Parsons, S.; Smith, E. C. R.; Wagner, J. R.; Yan, L.; Zhang, F.; Yingling, J. M. Bioorg. Med. Chem. Lett. 2004, 14, preceding paper doi:10.1016/j.bmcl.2004.04.007
2. Callahan J.F., Burgess J.L., Fornwald J.A., Gaster L.M., Harling J.D., Harrington F.P., Heer J., Kwon C., Lehr R., Mather A., Olson B.A., Weinstock J., Laping N.J. J. Med. Chem. 45:2002;999-1001
3. Sawyer J.S., Anderson B.D., Beight D.W., Campbell R.M., Jones M.L., Herron D.K., Lampe J.W., McCowan J.R., McMillen W.T., Mort N., Parsons S., Smith E.C.R., Vieth M., Weir L.C., Yan L., Zhang F., Yingling J.M. J. Med. Chem. 46:2003;3953-3956
4. (c) Sawyer, J. S.; Beight, D. W.; Ciapetti, P.; Decollo, T. V.; Godfrey, A. G.; Goodson, T.; Herron, D. K.; Li, H.; Liao, J.; McMillen, W. T.; Miller, S. C.; Yingling, J.; Smith, E. C. PCT Int. Appl. WO 0294833, 2002
5. Prashad M., Hu B., Lu Y., Draper R., Bar D., Repic O., Blacklock T.J. J. Org. Chem. 65:2000;2612-2614
6. Wieser R., Wrana J.L., Massague J. EMBO J. 14:1995;2199-2208
7. (a) Minami, N.; Sato, M.; Hasumi, K.; Yamamoto, N.; Keino, K.; Matsui, T.; Kanada, A.; Ohta, S.; Saito, T.; Sato, S.; Asagarasu, A.; Doi, S.; Kobayashi, M.; Sato, J.; Asano, H. PCT Int. Appl. WO 0075131, 2000
8. (b) Anantanarayan, A.; Clare, M.; Collins, P.; Crich, J.; Devraj, R.; Flynn, D. L.; Geng, L.; Graneto, M. J.; Hanau, C. E.; Hanson, G. J.; Hartmann, S. J.; Hepperle, M.; Huang, H.; Khanna, I. K.; Koszyk, F. J.; Liao, S.; Metz, S.; Partis, R. A.; Perry, T. D.; Rao, S. N.; Selness, S. R.; South, M. S.; Stealey, M. A.; Talley, J. J.; Vazquez, M. L.; Weier, R. M.; Xu, X.; Yu, Y. PCT Int. Appl. WO 0031063, 2000
9. Salituro F.G., Germann U.A., Wilson K.P., Bemis G.W., Fox T., Su S.-S. Curr. Med. Chem. 6:1999;807-823
10. Differences in rank-order potency between the enzyme and cell-based assays are due to physiochemical differences among the compounds tested, in addition to the nature of the enzyme assay (autophosphorylation) versus that of the cellular assays (substrate-phosphorylation)
11. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M., Wang X.F., Massague J. Cell. 71:1992;1003-1014
12. Leof E.B., Prpper J.A., Goustin A.S., Shipley G.D., DiCorleto P.E., Moses H.L. Proc. Natl. Acad. Sci. U.S.A. 71:1986;1003-1014